PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTI-CD38 ANTIBODY AND A HYALURONIDASE

AR135193A1Pending Publication Date: 2026-07-22JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
ARP20250100327
Authority / Receiving Office
AR · AR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-11-03
Filing Date
2025-02-06
Publication Date
2026-07-22
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.

Claims

The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

1. A pharmaceutical composition characterized in that it comprises: a) an anti-CD38 antibody comprising a heavy chain variable region (HV) of SEQ ID No. 4 and a light chain variable region (LV) of SEQ ID No. 5; and b) recombinant hyaluronidase rHuPH20, wherein the pharmaceutical composition comprises 1,800 mg of the anti-CD38 antibody and has a hyaluronidase enzyme activity of 30,000 U.

7. A pharmaceutical composition characterized in that it comprises daratumumab, histidine, sorbitol and a surfactant, wherein the turbidity of the pharmaceutical composition is approximately 6 Nephelometric Turbidity Units (NTU) or less after storage for 1 month at 25°C and 60% relative humidity.